Crossmark

GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1007/s00066-016-0941-8

Published Online: 2016-01-25

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Flentje, Michael

Huber, Rudolf M.

Engel-Riedel, Walburga

Andreas, Stefan

Kollmeier, Jens

Staar, Susanne

Dickgreber, Nicolas

Vaissiere, Nathalie

De Almeida, Cecilia

Edlich, Birgit

Fietkau, Rainer
License Information

Text and Data Mining valid from 2016-01-25

Version of Record valid from 2016-01-25
More Information

Article History

Received: 15 October 2015

Accepted: 8 January 2016

First Online: 25 January 2016

Change Date: 18 September 2025

Change Type: Update

Change Details: The missing ESM Figure, Table 1 and Table 2 are updated.

Compliance with ethical guidelines

:

: JK reports grants to his institution by Pierre Fabre; SA reports financial support by Roche, GlaxoSmithKline, Boehringer Ingelheim and Eli Lilly; RH reports funding by Pierre Fabre; RF reports financial support by Pierre Fabre, Roche and Eli Lilly; MF reports funding by Pierre Fabre. NV, CDA and BE are employees of Pierre Fabre. WER, SS and ND state that there are no conflicts of interest.

: All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form). Informed consent was obtained from all patients included in studies.

Document is current

Any future updates will be listed below